Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

The anti-tumor mechanisms of p53 through the regulation of expression and glycosylation of insulin-like growth factor binding protein-3

암억제 유전자 p53에 의한 insulin-like growth factor binding protein-3의 발현과 glycosylation를 통한 항암작용

  • Kim, Sun Young (Research Institute of Clinical Medicine, Chonbuk National University) ;
  • Kim, Se Rim (Research Institute of Clinical Medicine, Chonbuk National University) ;
  • Lee, Jung Chang (Department of Biochemistry, School of Dentistry, Chonbuk National University) ;
  • Yi, Ho Keun (Department of Biochemistry, School of Dentistry, Chonbuk National University) ;
  • Lee, Dae Yeol (Department of Pediatrics, School of Medicine, Chonbuk National University) ;
  • Hwang, Pyoung Han (Department of Pediatrics, School of Medicine, Chonbuk National University)
  • 김선영 (전북대학교 의과대학 임상의학연구소) ;
  • 김세림 (전북대학교 의과대학 임상의학연구소) ;
  • 이정창 (전북대학교 의과대학 치과대학 생화학교실) ;
  • 이호근 (전북대학교 의과대학 치과대학 생화학교실) ;
  • 이대열 (전북대학교 의과대학 소아과학교실) ;
  • 황평한 (전북대학교 의과대학 소아과학교실)
  • Received : 2005.10.31
  • Accepted : 2005.11.30
  • Published : 2006.04.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Insulin-like growth factor binding protein(IGFBP)-3 has been known as a tumor suppressor gene, and its anti-tumor function was divided into insulin-like growth factor(IGF)-dependent and IGF-independent mechanism. In IGF-independent mechanism, IGFBP-3 directly interacts with a cell without binding of IGFs, becoming an interesting object in oncology. Several studies demonstrate that one of the well-known tumor suppressor genes, p53, induces directly IGFBP-3 transcription, and the increment of IGFBP-3 expression induces apoptosis of many cancer cells. Recently, the anti-tumor mechanisms of IGFBP-3 have been reported, but post-translational modification of IGFBP-3 and its anti-tumor mechanism are not well known. In this study, we examined whether p53 regulated the glycosylation of IGFBP-3, and analysed the meaning of IGFBP-3 glycosylation related to the apoptosis of cancer cell. Methods : The p53-mutated status of MDA-MB-231 human breast cancer cells was used in this experiment. The expression and glycosylation of IGFBP-3 were tested by Western blot analysis after infection of adenovirus mediated Ad/p53 and/or Ad/IGFBP-3. Results : Ad/p53 infected cells resulted in growth retardation and the induced apoptosis. p53 induced direct expression and glycosylation of IGFBP-3. The increase of glcosylated IGFBP-3 was able to promote cellular apoptosis, and the glycosylation of IGFBP-3 was more activated by the double treatment of Ad/p53 and Ad/IGFBP-3. Conclusion : From this study, the anti-tumor activity of IGFBP-3 was shown to improve the stabilization of IGFBP-3 through the increment of glycosylation of IGFBP-3 by p53. This result suggests that the combined gene therapy of p53 and IGFBP-3 may appropriate treatment of cancer.

목 적 : 새로운 암억제 유전자로 알려진 IGFBP-3의 주요 기능은 IGF-I과 IGF-II와 결합을 하여 IGF의 기능을 조절하는 IGF dependent mechanism과 IGFBP-3 자체가 IGF와 결합과는 무관하게 세포의 apoptosis를 유도하는 IGF independent mechanism이 보고되었다. 암억제 유전자 p53의 대표적인 항암 기전의 하나는 직접 IGFBP-3의 발현을 증가시키며, 발현된 IGFBP-3는 암세포의 apoptosis를 유도시킨다. IGFBP-3의 항암작용은 보고되었지만, IGFBP-3의 변역 후 변형에 의한 항암기전은 전혀 밝혀져 있지 않다. 본 연구에서는 p53의 항암기전과 관련하여 IGFBP-3의 당화에 관련된 기전을 밝히고, IGFBP-3 당화의 의미를 규명하였다. 방 법 : 실험 세포주로는 p53의 변이를 보이며 p53의 발현이 일반세포에 비교하여 낮은 특징을 갖고 있는 사람의 유방암세포인 MDA-MB-231를 사용하였으며, Ad/p53과 Ad/IGFBP-3 아데노바이러스를 감염시킨 후 IGFBP-3의 발현 변화와 apoptosis 기전을 분석하였다. glycosylation 억제제로 알려져 있는 tunicamycin을 처리하여 당화의 정도를 조사하였다. 결 과 : 실험 세포에 Ad/p53을 감염시켜 p53을 발현시킨 결과 성장의 억제와 apoptosis가 유도되었고, IGFBP-3의 발현이 현저하게 증가되었으며, 특히 IGFBP-3의 당화 형태를 증가시켰다. 당화된 IGFBP-3의 증가는 세포의 apoptosis의 유도가 촉진되었으며, 이러한 IGFBP-3의 당화는 p53과 IGFBP-3의 발현을 동시에 유도시킨 결과 더욱 항진되었다. 결 론 : 이상의 연구에서 IGFBP-3의 암억제 능력의 향상은 p53에 의한 IGFBP-3의 당화의 증가를 통하여 안정화됨으로서 나타나고 있음을 알 수 있었다. 이는 p53과 IGFBP-3를 이용한 혼합유전자 치료가 가능할 것으로 사료된다.

Keywords

Acknowledgement

Supported by : 전북대학교병원

References

  1. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor- binding proteins in serum and other biological fluids : regulation and functions. Endocr Rev 1997;18:801-31 https://doi.org/10.1210/er.18.6.801
  2. Daughaday WH, Rotwein P. Insulin-like growth factors I and II : peptide messenger ribonucleic acid and gene structures serum and tissue concentrations. Endocr Rev 1989;10: 68-91 https://doi.org/10.1210/edrv-10-1-68
  3. Foustion AS, Leoff EB, Shipley GD, Moses HL. Growth factors and cnacer. Cancer Res 1986;46:1015-29
  4. Froesch ER, Schmidt Chr, Schwander J, Zapf J. Action of insulin-like growth factors. Annu Rev Physiol 1985;47:443- 67 https://doi.org/10.1146/annurev.ph.47.030185.002303
  5. Blatt J, White C, Dienes S, Friedman H, Foley T. Production of an insulin-like growth factor by osteosarcoma. Biochem Biophys Res Commun 1984;123:373-9 https://doi.org/10.1016/0006-291X(84)90423-6
  6. Reeve AE, Eccles MR, Wilkins RJ, Bell GI, Millow LJ. Expression of insulin-like growth factor II transcripts in Wilm's tumor. Nature 1985;317:258-60 https://doi.org/10.1038/317258a0
  7. Tricoli JV, Rall LB, Karakousis CP, Herrera L, Petrelli NJ, Bell GI, et al. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 1986;46:6169-73
  8. Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB. Secretion of an insulin-like growth factor- I-related protein by human breast cancer cells. Cancer Res 1986;46:4613-9.
  9. Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC, Cavenee WK. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 1985;316:330-4 https://doi.org/10.1038/316330a0
  10. Huff KK, Knabbe C, Lindsey R, kaufman D, Bronzert D, Lippman ME, et al. Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells. Mol Endocrinol 1988;2:200-8 https://doi.org/10.1210/mend-2-3-200
  11. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor- binding proteins in serum and other biological fluids : regulation and functions. Endocr Rev 1997;18:801-31 https://doi.org/10.1210/er.18.6.801
  12. Shimasaki S, Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Progress Growth Factor Res 1991;3:243-66 https://doi.org/10.1016/0955-2235(91)90003-M
  13. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor(IGF)-independent action of IGF-binding protein- 3 in Hs578T human breast cancer cells. J Biol Chem 1993;268:14964-71
  14. Oh Y. IGFBPs and neoplastic models : new concept for roles of IGFBPs in regulation of cancer cell growth. Endocrine 1997;7:111-3 https://doi.org/10.1007/BF02778076
  15. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-${\beta}$-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995;270: 13589-92 https://doi.org/10.1074/jbc.270.23.13589
  16. Gucev ZS, Oh Y, Kelly KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid and transforming growth factor ${\beta}$2-induced growth inhibition in human breast cancer cells. Cancer Res 1996;56:1545-50
  17. Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996;271:1016-21 https://doi.org/10.1074/jbc.271.2.1016
  18. Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 1998;20:157-62 https://doi.org/10.1677/jme.0.0200157
  19. Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 1998;13:865-9
  20. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646-9 https://doi.org/10.1038/377646a0
  21. Mochizuki S, Shimoda M, Shiomi T, Fujii Y, Okada Y. ADAM28 is activated by MMP-7(matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun 2004;315:79-84 https://doi.org/10.1016/j.bbrc.2004.01.022
  22. Kübler B, Cowell S, Zapf J, Braulke T. Proteolysis of insulin- like growth factor binding proteins by a novel 50- kilodalton metalloproteinase in human pregnancy serum. Endocrinology 1998;139:1556-63 https://doi.org/10.1210/en.139.4.1556
  23. Kim HS, Ingermann AR, Tsubaki J, Twigg SM, Walker GE, Oh Y. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor- mediated pathway in MCF-7 human breast cancer cells. Cancer Res 2004;64:2229-37 https://doi.org/10.1158/0008-5472.CAN-03-1675
  24. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiationinduced apoptosis in human breast cancer cells. J Biol Chem 2000;275:39174-81 https://doi.org/10.1074/jbc.M908888199
  25. Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer : a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci USA 1975;72:5116-20 https://doi.org/10.1073/pnas.72.12.5116
  26. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science 1991;253:49-53 https://doi.org/10.1126/science.1905840
  27. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6 https://doi.org/10.1016/S0140-6736(97)10384-1
  28. Pratt SE, Pollak MN. Estrogen and antiestrogen modulation of MCF-7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulinlike growth factor-binding proteins in conditioned media. Cancer Res 1993;53:5193-8
  29. Mohan S, Bautista CM, Wergedal J, Baylink DJ. Isolation of an inhibitory insulin-like growth factor(IGF) binding protein from bone cell-conditioned medium : a potential local regulator of IGF action. Proc Natl Acad Sci USA 1989; 86:8338-42 https://doi.org/10.1073/pnas.86.21.8338
  30. Thiery J, Abouzahr S, Dorothee G, Jalil A, Richon C, Vergnon I, et al. p53 Potentiation of tumor cell susceptibility to CTL involves Fas and mitochondrial pathways. J Immunol 2005;174:871-8 https://doi.org/10.4049/jimmunol.174.2.871